Detailed Narrative
Q3 and 9M FY26 Financial Performance Overview
Mankind Pharma reported a robust Q3 FY26 with overall revenue increasing by 11.5% year-on-year to INR3,567 crores. For the first nine months of FY26, revenue grew by 18.7% year-on-year to INR10,835 crores. The adjusted EBITDA margin for Q3 stood at 25.9%, while the 9M adjusted EBITDA margin was 24.9%, aligning with the lower end of the company's guidance. PAT for Q3 grew 9.5% year-on-year to INR414 crores, with diluted EPS at INR9.9 per share.
Domestic Business Growth and Segment Performance
The domestic business recorded an 11.1% year-on-year growth in Q3, with organic growth (excluding OTC) at 9.1%. For the nine-month period, domestic revenues increased by 14.8% to INR9,331 crores. Chronic therapies continued their strong momentum, growing 16.7% in cardio and 14.4% in antidiabetes in Q3, and their contribution to 9M revenue increased by 200 bps to 36.7%. The inhaler portfolio grew 30%, and new launches like Vonalong (gastro) and Crenzlo (cardio) achieved 86% and 92% year-on-year growth respectively, securing top ranks in their categories.
OTC and International Business Performance
The OTC business saw a 5.2% year-on-year growth in Q3, with key brands like Gas-O-Fast, Manforce, and Ova News growing 33%, 8%, and 36% respectively in secondary sales. Modern trade and e-commerce channels contributed 13% to OTC sales, growing over 40%. International business exports grew 14% year-on-year to INR521 crores in Q3, and 51% to INR1,503 crores for the nine-month period. The BSV business delivered double-digit growth in Q3, with its 9-month prescription business surpassing FY25 sales.
Margin Dynamics and R&D Investment
Gross margins improved by 170 basis points year-on-year to 72.6% in Q3 FY26. However, the adjusted EBITDA margin saw a 170 bps decline, primarily attributed to a 70 bps increase in R&D costs and higher employee expenses. R&D expenses for Q3 were INR102 crores, representing 2.9% of sales, which is within the full-year guidance of 2.5% to 3%. The reported EBITDA margin was further impacted by 300 bps due to exceptional item📎s, including New Labour Code adoption and impairment of noncurrent surplus assets.
Capital Structure and Debt Management
Mankind Pharma demonstrated prudent financial management, reducing its net debt to INR4,294 crores as of December 31, 2025. This led to an improved net debt to adjusted EBITDA ratio of 1.3x on a trailing 12-month basis, down from 1.4x in the previous quarter. The finance cost decreased to INR157 crores in Q3, driven by the repayment of INR1,500 crores worth of commercial papers in October 2025. The CFO to EBITDA ratio for 9M FY26 significantly improved to 93% from 68% in 9M FY25, aided by working capital optimization and realization of government receivables.
Strategic Transformation and Cultural Integration Challenges
Management acknowledged that a significant transformation over the past 12-15 months, involving hiring 15-20% new field force and leadership, led to initial challenges. Overestimation of cultural integration and subsequent insecurity among employees resulted in attrition and muted growth in certain segments, particularly acute and anti-infectives. However, management asserted that these issues are now understood, corrective actions are in place, and the company is back on track, with improving workforce stability and confidence.